Asymmetric α-Anordrin Therapy for Safer Estrogen Deficiency Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing estrogen replacement therapies for treating estrogen-deficiency symptoms, such as those experienced by ovariectomized or postmenopausal women, are associated with increased risks of breast and uterine cancer, thromboembolism, and significant side effects, necessitating the development of safer and more effective treatments.
Innovation Solution
The synthesis of a diastereomeric compound, such as α-anordrin, or its salt, which is administered alone or in combination with selective estrogen receptor modulators or aromatase inhibitors, to treat estrogen deficiency symptoms and reduce side effects, including high liver triglycerides, osteoporosis, vulvovagina atrophy, high blood triglycerides, high blood glucose, and weight gain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If estrogen replacement therapy (ERT) is used to treat estrogen-deficiency symptoms, then the quality of life is improved, but the risk of breast and uterine cancer increases
Solution Approach 1:
The patent segments the estrogen replacement therapy into two distinct components: a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast and uterine tissues, and a diastereomeric compound that acts as an agonist in bone and cardiovascular tissues. This segmentation allows different tissue-specific effects to be achieved simultaneously, improving quality of life while reducing cancer risk.
Solution Approach 2:
The patent applies local quality by using a SERM that provides tissue-selective estrogenic effects. The SERM acts as an antagonist in breast and uterine tissues (reducing cancer risk) while the diastereomeric compound provides agonist effects in bone and cardiovascular tissues (improving quality of life). Each component has different pharmacological properties tailored to specific tissue needs.
2Object-affected harmful factors
If combined administration of estrogen and progesterone is used to prevent breast and uterine cancers, then the cancer risk is reduced, but progesterone side effects occur
Solution Approach 1:
The patent extracts the cancer-preventive function from progesterone by using a SERM instead. The SERM provides the necessary uterine protection without the detrimental side effects of progesterone such as dizziness, nausea, vomiting, fatigue, anxiety, depression, and headache. The diastereomeric compound provides the estrogenic effects needed for bone and cardiovascular health.
Solution Approach 2:
The patent introduces a SERM as an intermediary substance that mediates the protective effect against breast and uterine cancer without requiring progesterone. The SERM acts as a selective antagonist in these tissues, providing cancer prevention while avoiding the systemic side effects associated with progesterone administration.
3Ease of operation
If traditional estrogen replacement therapy is used, then estrogen-deficiency symptoms are treated, but significant side effects occur
Solution Approach 1:
The patent segments the therapeutic approach into two distinct pharmacological agents with different mechanisms of action: a SERM that provides tissue-selective antagonism in breast and uterine tissues, and a diastereomeric compound that provides agonist effects in bone and cardiovascular tissues. This segmentation eliminates the need for high-dose estrogen therapy and its associated side effects.
Solution Approach 2:
The patent applies local quality by using agents with tissue-specific pharmacological properties. The SERM provides localized antagonist effects in breast and uterine tissues, while the diastereomeric compound provides localized agonist effects in bone and cardiovascular tissues. This targeted approach treats estrogen-deficiency symptoms while minimizing systemic side effects.
Data Source
AI summary
The present application discloses, among other things, asymmetric synthesis a diastereomeric compound of formula (I) (e.g., α-anordrin) or salt thereof. Also provided are methods and compositions for treatment of estrogen deficiency as well as preventing or reducing an estrogen deficiency symptom using a diastereomeric compound of formula (I) (e.g., α-anordrin) or salt thereof alone or in combination with at least one additional agent. Further provided are methods and compositions for reducing a side effect of an additional agent in the context of combination therapy with a diastereomeric compound of formula (I) (e.g., α-anordrin) or salt thereof.